Agreement of amyloid PET and CSF biomarkers in a clinical cohort

Abstract Background The amyloid deposition (A) in the 2018 ATN classification of Alzheimer disease can be assessed by CSF Aβ 1‐42 or PET. Although agreement between them is high, it not exact. Method We selected patients from Alzheimer’s and other cognitive disorders Unit at Hospital Clínic Barcelona with available PET lumbar puncture, a maximum difference time one half year them. used F18 Florbetapir (n=27), Florbetaben (n=7), Flutemetamol (n=16) 11C‐PIB (n=2) as tracers for 1‐42, total tau (tTau) phosphorylated (pTau) were measured using INNOTEST ® Fujirebio until June 2019 LUMIPULSE after 2019. analyzed biomarkers. Result included 52 patients. They had been diagnosed (n=32), frontotemporal dementia (n=11), Lewy body psychiatric (n=7) (Table 1). There was perfect biomarkers when all normal altered (Figure 1): All A+T+N+ (n=19) positive A‐T‐N‐ negative Agreement decreased results. Only 11/19 A+T‐N‐ 31/32 (97%) low levels (A+) but only 11/20 (55%) (A‐). Conclusion showed altered. For results, much lower.